BioMarin at Wells Fargo conference: growth, pipeline and integration

At the Wells Fargo 21st Annual Healthcare Conference, CONMED Corporation (CNMD) highlighted its growth prospects despite facing challenges. Management emphasized strong execution in minimally invasive surgery, higher margins, and an expanding international presence as key factors supporting future growth. Revenue for 2025 grew by 5.1%, and earnings per share expanded at a double-digit rate.

For 2026, the company anticipates revenue growth of 5% to 6%, with a possible acceleration to 6% to 8% in the second half of the year, driven by products such as AirSeal, BioBrace, and Buffalo Filter. CONMED's international operations contribute 45% of sales and are benefiting from regulatory approvals in regions like Europe and Brazil.

Gross margins are expected to improve by 50 to 100 basis points, and free cash flow is anticipated to increase through better inventory and working capital management. The company sees opportunities for strategic acquisitions but prioritizes de-leveraging before pursuing larger deals. CEO Pat Beyer stated that CONMED is evolving into a faster-growing company with improved operating leverage.